| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41392-020-00264-X |
| P698 | PubMed publication ID | 32782275 |
| P2093 | author name string | Jian Zhou | |
| Xin-Rong Yang | |||
| Ashley R Dennison | |||
| Ao Huang | |||
| Wen-Yuan Chung | |||
| P2860 | cites work | Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort | Q93068290 |
| Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma | Q94659990 | ||
| NCI-MATCH trial pushes cancer umbrella trial paradigm | Q95416330 | ||
| Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis | Q95459974 | ||
| Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study | Q96165774 | ||
| Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib | Q93047890 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| A new initiative on precision medicine | Q29615654 | ||
| Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. | Q33382749 | ||
| Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 | ||
| Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study | Q33415172 | ||
| First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study | Q33420684 | ||
| Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | Q33423800 | ||
| Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20. | Q33443438 | ||
| Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. | Q33907588 | ||
| Patient-derived xenograft models: an emerging platform for translational cancer research | Q34205518 | ||
| Cancer heterogeneity: implications for targeted therapeutics | Q34321565 | ||
| Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 | ||
| Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening | Q34701235 | ||
| Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 | ||
| Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade | Q35065472 | ||
| Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution | Q35839634 | ||
| Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets | Q36104399 | ||
| SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma | Q36140832 | ||
| Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease | Q36357360 | ||
| Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study | Q36404761 | ||
| Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma | Q36547263 | ||
| Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma | Q36598514 | ||
| Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study | Q36720049 | ||
| Adjuvant sorafenib for liver cancer: wrong stage, wrong dose | Q36739406 | ||
| Focal gains of VEGFA and molecular classification of hepatocellular carcinoma | Q36984575 | ||
| Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients | Q37012378 | ||
| Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center | Q37380454 | ||
| Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer | Q37495410 | ||
| Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. | Q37580172 | ||
| Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis | Q37688967 | ||
| Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma | Q37696388 | ||
| Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence | Q37701106 | ||
| Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma | Q37710134 | ||
| Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. | Q38122306 | ||
| Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study | Q38202696 | ||
| A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). | Q38387061 | ||
| Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score | Q38387245 | ||
| Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial | Q38388551 | ||
| Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets | Q38400913 | ||
| Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma | Q38635603 | ||
| Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. | Q38702281 | ||
| Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. | Q38711169 | ||
| Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features | Q38721035 | ||
| Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study | Q38737964 | ||
| Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents. | Q38745776 | ||
| Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future | Q38758819 | ||
| Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma | Q38778021 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| Global trends and predictions in hepatocellular carcinoma mortality | Q38881149 | ||
| The Impact of Early Dermatologic Events in the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib. | Q38944418 | ||
| Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. | Q39009644 | ||
| Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma | Q39031722 | ||
| Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature | Q39044741 | ||
| Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. | Q39175179 | ||
| αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma | Q39211222 | ||
| FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma | Q39297937 | ||
| Liver resection after downstaging hepatocellular carcinoma with sorafenib | Q39446538 | ||
| Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study | Q39548624 | ||
| Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial | Q39653331 | ||
| Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma | Q39929763 | ||
| Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study | Q39979280 | ||
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Q40231174 | ||
| Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial | Q40548309 | ||
| Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma | Q40846805 | ||
| Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma | Q40987028 | ||
| Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study | Q41024086 | ||
| Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma | Q41187204 | ||
| Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience | Q41496721 | ||
| Intratumor heterogeneity in hepatocellular carcinoma | Q42186312 | ||
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial | Q43522867 | ||
| Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 | ||
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial | Q44089673 | ||
| Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma | Q45275265 | ||
| Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study | Q45785329 | ||
| Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma. | Q46204388 | ||
| Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study | Q47094775 | ||
| Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma. | Q47165734 | ||
| Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma | Q47225007 | ||
| Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial | Q47376936 | ||
| Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. | Q47554590 | ||
| Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. | Q47788877 | ||
| Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma | Q48099309 | ||
| Single cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. | Q48282479 | ||
| A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. | Q48574942 | ||
| Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option | Q49402953 | ||
| Spatial Tissue Proteomics Quantifies Inter- and Intratumor Heterogeneity in Hepatocellular Carcinoma (HCC). | Q49832163 | ||
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Q50046367 | ||
| Immune-Related Adverse Events Associated with Immune Checkpoint Blockade | Q50103276 | ||
| Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment | Q50169188 | ||
| Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. | Q50671717 | ||
| Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation. | Q50767199 | ||
| A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. | Q52599927 | ||
| Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. | Q52684456 | ||
| Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study. | Q52728559 | ||
| Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. | Q52757804 | ||
| Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. | Q52900635 | ||
| Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. | Q53112763 | ||
| Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. | Q53449774 | ||
| Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. | Q53707065 | ||
| Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. | Q53803543 | ||
| Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study. | Q53818396 | ||
| A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. | Q53826807 | ||
| Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. | Q53837211 | ||
| Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. | Q54362470 | ||
| Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study. | Q55259389 | ||
| Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial | Q56355520 | ||
| Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma | Q56373211 | ||
| Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma | Q57214428 | ||
| Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition) | Q57494813 | ||
| Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses | Q57756652 | ||
| Anti-PD-1 Antibody SHR-1210 combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study | Q57801964 | ||
| Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial | Q58020775 | ||
| Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma | Q58089680 | ||
| Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma | Q58544320 | ||
| Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis | Q58588183 | ||
| Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib | Q59185719 | ||
| Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion: A case report | Q59349475 | ||
| Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study) | Q59795984 | ||
| Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model | Q59797774 | ||
| The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension | Q59799447 | ||
| Safety of Liver Resection for Hepatocellular Carcinoma After Sorafenib Therapy: A Multicenter Case-Matched Study | Q60641631 | ||
| Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy? | Q60912071 | ||
| Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib | Q60954607 | ||
| Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis | Q61054484 | ||
| Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis | Q61455444 | ||
| Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma | Q64094384 | ||
| Transarterial Chemoembolization (TACE) Combined with Sorafenib TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study | Q64237893 | ||
| 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma | Q64272871 | ||
| Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. | Q64930871 | ||
| The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study. | Q64962531 | ||
| Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation. | Q64985970 | ||
| Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma | Q84240690 | ||
| NCI-MATCH launch highlights new trial design in precision-medicine era | Q85528297 | ||
| Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection | Q85847965 | ||
| Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study | Q86786798 | ||
| Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice | Q87167977 | ||
| VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study | Q87259569 | ||
| Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma | Q87900984 | ||
| Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification | Q88230772 | ||
| EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma | Q88301343 | ||
| Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice | Q88437733 | ||
| Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment | Q88558587 | ||
| The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients | Q88732152 | ||
| Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy | Q88914229 | ||
| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Q89012806 | ||
| Circulating Tumor DNA Assays in Clinical Cancer Research | Q89183577 | ||
| Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells | Q89235521 | ||
| Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial | Q89951585 | ||
| Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers | Q90003849 | ||
| Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma | Q90099671 | ||
| CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma | Q90099879 | ||
| Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway | Q90146908 | ||
| Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma | Q90199717 | ||
| Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma | Q90208678 | ||
| Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma | Q90318939 | ||
| Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas | Q90330876 | ||
| Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis | Q90446223 | ||
| International trends in hepatocellular carcinoma incidence, 1978-2012 | Q90612954 | ||
| Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice | Q90633339 | ||
| Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial | Q90727327 | ||
| Comprehensive molecular and immunological characterization of hepatocellular carcinoma | Q90832177 | ||
| Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma | Q90848551 | ||
| Emerging agents and regimens for hepatocellular carcinoma | Q90958064 | ||
| Safety and Efficacy of Transcatheter Arterial Chemoembolization Plus Radiotherapy Combined With Sorafenib in Hepatocellular Carcinoma Showing Macrovascular Invasion | Q91083985 | ||
| Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report | Q91111514 | ||
| Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Q91147767 | ||
| Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings | Q91253554 | ||
| Clonal evolution in long-term follow-up patients with hepatocellular carcinoma | Q91294508 | ||
| MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1 | Q91317607 | ||
| Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma | Q91432940 | ||
| Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience | Q91454010 | ||
| Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment | Q91593715 | ||
| Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial | Q91603429 | ||
| Tumour evolution in hepatocellular carcinoma | Q91621531 | ||
| Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial | Q91697434 | ||
| Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study | Q91716418 | ||
| Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials | Q91723916 | ||
| Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response | Q91824075 | ||
| Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial | Q91879742 | ||
| Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma | Q91891911 | ||
| Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification | Q91917989 | ||
| Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib | Q91942671 | ||
| Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma | Q91987072 | ||
| Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression | Q92211224 | ||
| Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation | Q92309511 | ||
| Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study | Q92343733 | ||
| A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer | Q92380300 | ||
| Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma | Q92381776 | ||
| Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis | Q92462883 | ||
| Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis | Q92605149 | ||
| Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma | Q92646888 | ||
| Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma | Q92671554 | ||
| Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma | Q92754898 | ||
| A global view of hepatocellular carcinoma: trends, risk, prevention and management | Q92797759 | ||
| Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial | Q92830327 | ||
| Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study | Q92989160 | ||
| Hepatocellular Carcinoma | Q93002915 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 146 | |
| P577 | publication date | 2020-08-11 | |
| P1433 | published in | Signal Transduction and Targeted Therapy | Q108821959 |
| P1476 | title | Targeted therapy for hepatocellular carcinoma | |
| P478 | volume | 5 |
Search more.